摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactone | 81410-42-6

中文名称
——
中文别名
——
英文名称
3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactone
英文别名
3.4-dihydrotaiwanin C;5-benzo[1,3]dioxol-5-yl-8a,9-dihydro-8H-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-one;5-Benzo[1,3]dioxol-5-yl-8a,9-dihydro-8H-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on;5-(1,3-Benzodioxol-5-yl)-8a,9-dihydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8h)-one;5-(1,3-benzodioxol-5-yl)-8a,9-dihydro-8H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one
3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactone化学式
CAS
81410-42-6
化学式
C20H14O6
mdl
——
分子量
350.328
InChiKey
FARHQKNGMYOEBH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    573.0±50.0 °C(Predicted)
  • 密度:
    1.55±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    26
  • 可旋转键数:
    1
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    63.2
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactoneN-溴代丁二酰亚胺(NBS)过氧化氢苯甲酰 作用下, 以 四氯化碳 为溶剂, 反应 3.0h, 以31%的产率得到3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactone
    参考文献:
    名称:
    Studies on Disease-Modifying Antirheumatic Drugs. III. Bone Resorption Inhibitory Effects of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and Related Compounds.
    摘要:
    我们的研究旨在获得治疗骨关节疾病的新药物,在研究过程中,我们对强效骨吸收抑制剂刚烷类化合物进行了化学修饰,制备出了各种萘内酯、喹啉内酯以及侧链含有唑基的喹啉衍生物。研究发现,包括 4-(3,4-二甲氧基苯基)-6,7-二甲氧基-2-(1,2,4-三唑-1-基甲基)喹啉-3-羧酸乙酯(6c,TAK-603)在内的几种化合物具有与刚烷类化合物相当或更高的活性。尤其是 4-(3-异丙氧基-4-甲氧基)-苯基衍生物(6d),其药效明显增强。TAK-603 和化合物 6d 在阻止破骨细胞形成和成熟破骨细胞的骨吸收方面非常有效。此外,TAK-603 还能有效防止卵巢切除小鼠的骨质流失。
    DOI:
    10.1248/cpb.47.369
  • 作为产物:
    描述:
    (E)-3-(benzo[d][1,3]dioxol-5-yl)allyl 3-(benzo[d][1,3]dioxol-5-yl)propiolate乙酸酐 作用下, 反应 13.0h, 以78%的产率得到3,4-dihydro-3-hydroxymethyl-6,7-methylenedioxy-1-(3,4-methylenedioxyphenyl)naphthalene-2-carboxylic acid lactone
    参考文献:
    名称:
    Studies on Disease-Modifying Antirheumatic Drugs. III. Bone Resorption Inhibitory Effects of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and Related Compounds.
    摘要:
    我们的研究旨在获得治疗骨关节疾病的新药物,在研究过程中,我们对强效骨吸收抑制剂刚烷类化合物进行了化学修饰,制备出了各种萘内酯、喹啉内酯以及侧链含有唑基的喹啉衍生物。研究发现,包括 4-(3,4-二甲氧基苯基)-6,7-二甲氧基-2-(1,2,4-三唑-1-基甲基)喹啉-3-羧酸乙酯(6c,TAK-603)在内的几种化合物具有与刚烷类化合物相当或更高的活性。尤其是 4-(3-异丙氧基-4-甲氧基)-苯基衍生物(6d),其药效明显增强。TAK-603 和化合物 6d 在阻止破骨细胞形成和成熟破骨细胞的骨吸收方面非常有效。此外,TAK-603 还能有效防止卵巢切除小鼠的骨质流失。
    DOI:
    10.1248/cpb.47.369
点击查看最新优质反应信息

文献信息

  • New lignans from the heartwood of cleistanthus collinus
    作者:A.S.R. Anjaneyulu、P.Atchuta Ramaiah、L.Ramachandra Row、R. Venkateswarlu、A. Pelter、R.S. Ward
    DOI:10.1016/s0040-4020(01)98893-3
    日期:1981.1
    The isolation and characterisation of five new compounds and nine known compounds from the heartwood of Cleistanthus collinus are reported. The new compounds are wodeshiol 16,3,4-dihydrotaiwanin C 20, and three new glycosides 24, 25 and 26 of diphyllin and taiwanin E The 1H and 13C NMR spectra of these compounds are also reported.
    据报道,从Cleistanthus collinus的心材中分离并鉴定了五种新化合物和九种已知化合物。这些新化合物是wodeshiol 16,3,4- dihydrotaiwaninÇ 20,和三个新的苷24,25和26山荷叶素的和taiwanin E中的1 H和13这些化合物的C NMR谱也报道。
  • Regioselective route for arylnaphthalene lactones: convenient synthesis of taiwanin C, justicidin E, and daurinol
    作者:Ju-Eun Park、Juyeun Lee、Seung-Yong Seo、Dongyun Shin
    DOI:10.1016/j.tetlet.2013.12.014
    日期:2014.1
    selectivity. Herein, we report a convenient and regioselective synthesis method in which the intramolecular Diels–Alder reaction of an arylalkene–arylalkyne and subsequent DDQ oxidation was used for Type I and Type II arylnaphthalene lactones, respectively. We demonstrated the synthesis of three lignans, taiwanin C (Type I), justicidin E (Type II), and daurinol (Type I and anti-cancer activity).
    芳基萘内酯是可以从多种植物中分离得到的天然产物,并具有重要的生物学活性,包括细胞毒性,抗微生物剂,利尿剂和离子通道阻断作用。先前的3-芳基丙-2-炔基3-芳基丙酸酯的分子内Diels-Alder反应的缺点是无法选择性地生成两个芳基萘内酯的区域异构体。在这里,我们报告了一种方便且区域选择性的合成方法,其中芳基烯烃-芳基炔烃的分子内Diels-Alder反应和随后的DDQ氧化分别用于I型和II型芳基萘内酯。我们证明了三种木脂素的合成:黄花木素C(I型),木豆素E(II型)和柔红醇(I型和抗癌活性)。
  • Intramolecular Dehydro-Diels–Alder Reaction Affords Selective Entry to Arylnaphthalene or Aryldihydronaphthalene Lignans
    作者:Laura S. Kocsis、Kay M. Brummond
    DOI:10.1021/ol501853y
    日期:2014.8.15
    arylnaphthalene or aryldihydronaphthalene lactones selectively as determined by choice of reaction solvent. This constitutes the first report of an entirely selective formation of arylnaphthalene lactones utilizing DDA reactions of styrene-ynes. The synthetic utility of the DDA reaction is demonstrated by the synthesis of taiwanin C, retrohelioxanthin, justicidin B, isojusticidin B, and their dihydronaphthalene
    根据反应溶剂的选择,进行分子内脱氢-狄尔斯-阿尔德 (DDA) 反应,选择性地提供芳基萘或芳基二氢萘内酯。这构成了利用苯乙烯-炔的 DDA 反应完全选择性地形成芳基萘内酯的第一份报告。DDA 反应的合成效用通过 taiwanin C、retrohelioxanthin、justicidin B、isojusticidin B 及其二氢萘衍生物的合成得到证明。介绍了化学位移分配的计算方法,可以区分区域异构木脂素。
  • 170. The constituents of natural phenolic resins. Part VI. Synthesis of compounds related to cubebinolide (hinokinin)
    作者:Robert D. Haworth、William Kelly
    DOI:10.1039/jr9360000745
    日期:——
  • Studies on Disease-Modifying Antirheumatic Drugs. III. Bone Resorption Inhibitory Effects of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and Related Compounds.
    作者:Atsuo BABA、Tsuneo ODA、Shigehisa TAKETOMI、Kohei NOTOYA、Atsushi NISHIMURA、Haruhiko MAKINO、Takashi SOHDA
    DOI:10.1248/cpb.47.369
    日期:——
    In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the potent bone resorption inhibitors justicidins, was performed and various naphthalene lactones, quinoline lactones and quinoline derivatives bearing an azole moiety at the side chain were prepared. Their inhibitory effects on bone resorption were evaluated by Raisz's method, and several compounds, including ethyl 4-(3, 4-dimethoxyphenyl)-6, 7-dimethoxy-2-(1, 2, 4-triazol-1-ylmethyl)quinoline-3-carboxylate (6c, TAK-603), were found to have activities comparable with or superior to the justicidins. The 4-(3-isopropoxy-4-methoxy)-phenyl derivative (6d), in particular, displayed a marked increase in potency. TAK-603 and compound 6d were very effective in preventing osteoclast formation and bone resorption by mature osteoclasts. Further, TAK-603 was shown to be effective in preventing bone loss in ovariectomized mice.
    我们的研究旨在获得治疗骨关节疾病的新药物,在研究过程中,我们对强效骨吸收抑制剂刚烷类化合物进行了化学修饰,制备出了各种萘内酯、喹啉内酯以及侧链含有唑基的喹啉衍生物。研究发现,包括 4-(3,4-二甲氧基苯基)-6,7-二甲氧基-2-(1,2,4-三唑-1-基甲基)喹啉-3-羧酸乙酯(6c,TAK-603)在内的几种化合物具有与刚烷类化合物相当或更高的活性。尤其是 4-(3-异丙氧基-4-甲氧基)-苯基衍生物(6d),其药效明显增强。TAK-603 和化合物 6d 在阻止破骨细胞形成和成熟破骨细胞的骨吸收方面非常有效。此外,TAK-603 还能有效防止卵巢切除小鼠的骨质流失。
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮